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ABSTRACT 
Objective: To compare results from meta-analyses for mean differences in minimal important 
difference (MID) units (MDMID), when MID is treated as a random variable versus a constant. 
Study Design and Setting: Meta-analyses of published data. We calculated the variance of MDMID 
as a random variable using the delta method, and as a constant. We assessed performance under different 
assumptions. We compare meta-analysis results from data originally used to present the MDMID, and data 
from osteoarthritis studies using different domain instruments. 
Results: Depending on the data set and depending on the values of rho and CoV-MID, estimates 
of treatment effect and p-values between an approach considering the MID as a constant versus as a 
random variable may differ appreciably. Using our data sets, we provide examples of the potential 
magnitude. When rho=0.5 and CoVMID=0.8, considering MID as a constant overestimated the treatment 
effect by 33%-110%, and decreased the p-value for heterogeneity from above 0.95 to below 0.08. When 
rho=0.8 and CoVMID=0.5, the magnitude of the effects were similar. 
Conclusions: Considering MID as a random variable avoids unrealistic assumptions and provides 
more appropriate treatment effect estimates. 
 
Keywords: continuous outcomes; meta-analysis; minimal important difference; standardized mean 
difference; ratio of means; variance; methods 
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What is new? 
Key finding 
Current methods to standardize continuous outcomes in minimal important difference units 
require unrealistic assumptions 
What this adds to what was known? 
We describe a method to standardize continuous outcomes in minimal important difference units 
that allows for greater transparency of assumptions, and sensitivity analyses. 
What is the implication, what should change now? 
When standardizing continuous outcomes using minimal important difference units, investigators 
should incorporate realistic assumptions. 
Investigators should use sensitivity analyses to test the robustness of the results to violations of 
their assumptions. 
Some examples for GRADE Summary of Findings tables are provided. 
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INTRODUCTION 
Health care professionals are strongly encouraged to practice evidence-based medicine (EBM) [1-
4], where clinical decisions are based on the best evidence addressing a focused clinical question. 
Practicing EBM requires access to health care evidence, and preferably evidence that is succinctly and 
systematically summarised. When there is sufficient homogeneity of studies, a meta-analysis fulfils this 
objective. A meta-analysis may be broadly defined as the quantitative review and synthesis of the results 
from related but independent studies [5]; a trustworthy meta-analysis is always based on a thorough 
systematic review of the literature wherein the authors provide an overall quantitative summary statistic 
for the effect estimate of a group (or subgroup) of studies [6]. 
When the outcome is binary, investigators commonly combine studies in a meta-analysis by 
choosing to summarize across the risk difference, risk ratio or odds ratio scales [7, 8]. The magnitude and 
direction of the overall estimate may be different with different summary statistics because the formula 
for the variances (responsible for the weighting of individual studies) are different; the appropriate 
summary statistic for a particular meta-analysis may depend on the underlying reasons for variation in 
control group event rates; in some situations uncertainty about the choice of summary statistic will remain 
[9]. Therefore, to avoid introducing reporting bias, investigators should be explicit about why they chose 
the particular summary statistic for binary data [10]. 
When the outcome is continuous, systematic reviewers must calculate the treatment effect as 
either a raw mean difference (MD), or standardize the mean difference in some way [5].  Standardizing 
the mean difference is typically preferable when the construct being measured is the same across studies, 
but the actual measurement instrument differs. For example, frequently used pain measures for 
osteoarthritis [11] include the Western Ontario and McMaster University Osteoarthritis Index (WOMAC) 
[12], Knee Injury and Osteoarthritis Outcome Score (KOOS)/ Hip Disability and Osteoarthritis Outcome 
Score (HOOS) [13, 14], Visual Analogue Scales, Health Assessment Questionnaire (HAQ) (pain 
subscale) [15], Lequesne algofunctional index (pain subscale) [16], Arthritis Impact Measurement Scales 
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(AIMS) (pain subscale) [17, 18] and McGill Pain Questionnaire (pain intensity) [19]. When constructs are 
measured using different scales, combining the raw numbers into a weighted average is not meaningful 
because a result of 10 on one scale might be equivalent to a result of 50 on another scale. Therefore, some 
form of standardization is necessary before the results can be combined. 
Commonly proposed methods for standardization include the standardized mean difference 
(SMD) [20], ratio of means (RoM) [21, 22], and a more recent method based on standardizing the MD 
using minimal important differences (MID) between groups [23, 24]. Although the MID approach has 
recently been proposed as a simple effect measure to use, it considers MID as a constant. However, 
different patients will often have different values for MID, just as different people have different heights 
or weights. For example, if pain is rated on a scale of 0-10, one person might consider 2 as the MID, 
another 3 as the MID and another 1 as the MID. If we acknowledge that there is variation in the 
population, then in statistical terms, the MID is considered a random variable; taking the mean of the 
values as the one true value would be to treat MID as a constant.  
The distinction between treating MID as a constant versus a random variable is important. As a 
random variable, there would be an expected correlation between MD and MID, and there would be a 
coefficient of variation of MID. The value of these two variables will affect confidence intervals and 
statistical significance testing. The purpose of this paper is to highlight the overall benefits of treating 
MID as a random variable, and to illustrate how it can be implemented easily. We illustrate our proposed 
solution using two different datasets, (i) data originally pooled by Johnston et al. in their original study 
[23], and (ii) data from studies investigating the effects of exercise on knee osteoarthritis [25] that are 
well-known for using different scales to measure the same construct [11]. 
Finally, once the treatment effect is estimated (whether SMD, RoM, or MID units), authors have 
different options on how to present the results. The GRADE working group have suggested that summary 
of findings tables could include a comparative treatment effect such as mean difference, mean values for 
each group (by assuming a mean value for the control group and then estimating the mean for the 
treatment group based on the calculated treatment effect), or converting the continuous scale into 
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categories and reporting proportion of patients who would receive substantive benefit [26]. Although the 
objective of our paper is to estimate a valid treatment effect, the editors have asked us to illustrate how the 
results could be adapted into different formats for presentation to decision-makers. 
 
Proposed Standardization Methods 
The most commonly recommended and used method of standardization is the SMD [20, 27]. In 
brief, the mean difference from each study is divided by a pooled standard deviation (sd). Therefore, each 
study estimate is now expressed as an “effect size”, and these can be combined using standard inverse-
variance meta-analytical techniques. As discussed by the GRADE working group, the problem with this 
method is that two studies will have different effect estimates if the sd differs [26], even if they use the 
same scale, have the same mean difference, and have the same number of participants. Therefore, a study 
with a larger sd not only receives less weight (may sometimes be appropriate but can result in a bias 
towards the null [27]) but also has a reduced effect size and this leads to bias. Imagine a series of studies 
where all studies measured an outcome using two different scales (Scale A, Scale B). If one conducted a 
meta-analysis based on mean difference without standardization using only Scale A or only Scale B, the 
results are expected to be similar as long as both scales are measuring the same construct accurately. 
Now, consider that 50% of the studies lost their Scale A data (or never collected Scale A data), and the 
other 50% of the studies lost their Scale B data (or never collected Scale B data). The meta-analysis based 
on standardized mean differences would yield different (biased) results from the original meta-analysis 
using either Scale A or Scale B because the effect estimates are now dependent on the sd of the individual 
studies. In response to these challenges, two alternatives have recently been proposed. 
Friedrich et al. proposed to base the meta-analysis on the ratio of means (RoM) of the two groups 
[21, 22]. As a ratio, the effect estimate from each study has no units and can be combined. Further, the 
multiplicative nature of the RoM (e.g. the treated group has ½ the pain of the untreated group) is 
appealing for clinicians and patients because treatments are often discussed in these terms. However, this 
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is only appropriate if the treatment effect indeed occurs on the multiplicative scale. For example, a 
treatment might reduce pain by 4 units on a 10-point scale whether the baseline pain is 8 (final pain score 
= 4, RoM = 2) or 6 (final pain score = 2, RoM = 3), i.e. mean difference equals 4 for both studies. In this 
case, an additive scale would be less heterogeneous and more appropriate than the multiplicative scale of 
RoM.  
In 2010, Johnston et al. [23] proposed to standardize the mean difference (additive scale) by the 
MID. In this measure, the results from each study are represented as the number of MID units for the 
scale that was used. In the example above with a mean difference of 4, if the MID for the pain scale was 
2, both studies would decrease pain by 2 MID units. This standardization is appealing to clinicians for 
contexts requiring an additive scale because it has face validity and is easily interpretable. However, there 
are two challenges with Johnston et al.’s approach: 1) the calculation of the variance of the MD/MID 
ratio, and 2) many studies do not have an established MID. 
Obtaining a valid variance of individual studies in a meta-analysis is essential because variance 
affects both the point estimate of the overall meta-analysis estimate (dependent on a weighted average of 
the individual studies, where the weights for each study are based on their respective variances), the 
observed heterogeneity, and the uncertainty of the overall estimate (dependent on the sum of the 
individual variances in a fixed effects analysis, and the sum of the within and between study variances in 
a random effects analysis). To obtain the variance of the MID unit effect estimate, Johnston et al. 
considered the MID for a scale to be a constant [23].  
The variance of an estimate (e.g. mean difference) divided by a constant (e.g. MID) is simply the 
variance of the estimate divided the constant squared (MID2). Simplifying MID to a constant (i.e. one 
value) is a common practice, but introduces challenges. First, establishing an MID for a scale is difficult 
because the MID for one patient is different from another patient. Further, the MID may be dependent on 
the baseline value prior to treatment [28, 29]. Therefore, treating the MID as a constant appears to be an 
unrealistic assumption. Second, a meta-analysis using MID units requires that the MID be defined for 
each scale in the meta-analysis. Unfortunately, the MID for many scales has not been formally 
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investigated. To expand the use of the MID unit concept, Johnston et al. later recommended using a 
distribution-based method to impute the MID when it was unknown [24]. First, they divided the MID by 
the sd of each study that used a scale with a known MID, to obtain an MID/sd ratio for each study. This 
provided a range of MID/sd ratios. They considered the median from this range of values as the “official” 
MID/sd ratio for the outcome measured by the scale. In the final step, for each study without an MID, 
they multiplied the sd by the official MID/sd ratio to obtain an estimate of the MID for that scale. This 
simple calculation provides an easy solution but includes significant assumptions. First, the distribution 
method assumes the MID/sd ratio is constant across different scales. Second, the uncertainty of the 
estimate from studies using a known MID is treated the same as the uncertainty of the estimate from 
studies using an imputed value for MID. 
Our proposed solution is to consider the MID as a random variable instead of a constant. This 
approach addresses all of the limitations above. It enables investigators to obtain estimates of the mean 
difference standardized for MID (MDMID) for questionnaires with no previous MID and to avoid making 
the unrealistic assumptions that 1) all people would provide the same value for MID, 2) the coefficient of 
variation for MID is independent of the measure, and 3) there is no correlation between the MID and the 
MD.  
 
METHODS 
Variance Calculations (individual studies) 
The calculation for the variance of MDMID is simply the variance of a ratio (MD / MID). When 
the MID is considered a constant, the variance of the ratio is simply: 
 
	

  [eq.1] 
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where varianceMD is the variance of the difference in the group means, and MID is the proposed minimal 
important difference for the scale being used.  
When the MID is considered to have a distribution of values (random variable), the distribution 
can be summarized with a mean (meanMID) and sd (sdMID). The variance of the ratio that represents MDMID 
units (MD/MID) must now account for the correlation of the numerator and denominator of the ratio 
(rho), and the coefficient of variation (CoV) of the MID (sdMID / meanMID). Using the delta method and 
rearranging the equation to show the effect of CoVMID (see Appendix 1 for derivation), the variance of the 
ratio is [30]: 
  = 
 !"#
$!"%# − '2 ∗ rho ∗ sd/0 ∗ CoV
 ∗ 3
/0
$!"%#45	+	 83
/0
$!"%#4
9 ∗ :CoV
;9< [eq.2] 
 
where meanMID is the mean of the MID distribution (equal to the value of MID when MID is considered a 
constant), rho is the correlation between varianceMD and meanMID, sdMD is the pooled sd (between the two 
groups), and MD is the difference in group means. 
In equation 2, when MID is a constant without a distribution, CoVMID equals 0, the second and 
third terms each equal 0, and the formula collapses into equation 1. However, when MID has a 
distribution, equation 1 will underestimate or overestimate the variance depending on the balance of the 
second term (decreases variance) and third term (increases the variance) of equation 2. In brief, the 
variance will decrease as rho increases when CoVMID is held constant, and the variance will increase as 
the CoVMID increases when rho is held constant. Finally, everything else held constant, the effect on the 
variance increases as the mean difference between groups increases. This latter effect means greater care 
must be exercised when combining studies in a meta-analysis. Studies that use measures with poor 
sensitivity to change essentially have more measurement error or noise, which leads to higher sd (higher 
CoVMID and higher variance) and a lower mean difference (lower variance). The overall effect on 
variance would depend on the balance of factors. 
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Empiric Data 
Quality of Life in Chronic Obstructive Pulmonary Disease (COPD) 
We replicated the data set used to first report a meta-analysis in MID units (Figure 1) [23]. The 
MID for the Chronic Respiratory Disease Questionnaire (CRQ) was reported as 0.5 on a 7-point scale, 
and the MID for the St. Georges Respiratory Questionnaire (SGRC) was reported as 4 on a 100-point 
scale.  
 
Pain and Function in Patients with Osteoarthritis 
We also analyzed data from a meta-analysis from Fransen et al. [25] This systematic review 
investigated the effect of exercise on pain and disability for participants with osteoarthritis in the knee. As 
seen in Appendix 2 and 3, the scale (and the range of the score) differs largely between the included 
studies, even within the same instrument measure.  
RESULTS 
We now present three illustrative meta-analysis examples. First, we present the health related 
quality of life following rehabilitation in COPD data that was used in the original description of the MID 
effect estimate (Figure 2 in Johnston et al.[23]), and show the results of sensitivity analyses varying rho 
and CoVMID. Next, we apply the methods using data from meta-analyses investigating pain and disability 
following therapeutic exercise in knee osteoarthritis. 
To calculate the variance, one must enter values for two variables that are not completely known 
and must be evaluated carefully using sensitivity analyses. First, we held rho constant between 0 and 1.0 
in increments of 0.1, and varied CoVMID between 0, 0.2, 0.5, 0.8 and 1. As an illustrative example, Figure 
2 compares the square root of the variance (sd, in order to provide more spread between the points) 
between the two methods when rho is held constant at 0.5, and the CoVMID equals 0.2, 0.5 and 0.8. Each 
study is represented by its corresponding letter from Figure 1. The line of identify shows where the points 
would fall if MID were a constant (if CoVMID = 0, the two variance calculations are identical). The left 
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panel shows that the points are generally shifted to the left of the line of identity when CoVMID = 0.2. This 
means the calculated variance when MID is considered a constant (line of identity) overestimates the true 
variance at CoVMID = 0.2. This occurs because the second term in equation 2 will generally be greater 
than the third term of equation 2 if rho is large and CoVMID is small. Examining the change in the position 
of the points as CoVMID is increased, one sees the points generally move to the right, and the calculated 
variance when MID is considered a constant underestimates the true variance for the vast majority of 
studies. The effect is greatest when the treatment effect is greatest (“d” for SGRQ studies and “f”, “g”, “j” 
and “k” for the CRQ studies). 
Second, we conducted sensitivity analyses by holding CoVMID constant at 0.5 and calculating the 
variance when rho equaled 0, 0.5 and 0.8 (Figure 3). When rho is 0, the second term in equation 2 is 0, 
and the calculated variance when MID is considered a constant underestimates the true variance (points 
below the line of identity). As rho increases, the value of the second term in equation 2 increases and the 
points shift to the left. 
In these analyses, we assumed the same CoVMID for both measures for pedagogical reasons. If 
one measure had a greater sensitivity to change, the CoVMID might be different between instruments. This 
could have important effects on the overall summary effect estimate. Our results are based on extraction 
of summary data from published meta-analyses and are only intended to illustrate the importance of 
considering MID as a distribution. They should not be interpreted as true estimates for the effects of the 
treatments proposed, which would require a complete systematic review, evaluation of the original 
papers, and characterization (or determination of what are realistic assumptions) of the distribution of 
MID for each measurement instrument. 
Quality of Life in patients COPD, Pain and Disability in patients with Osteoarthritis 
Table 1 presents the meta-analysis results for the Johnston et al. data [23], and the data examining 
the effects of exercise on osteoarthritis for pain, and for disability [11], when rho equals 0.5 and MID is 
varied between 0.2, 0.5 and 0.8. For the osteoarthritis data, we estimated the MID for each scale based on 
our understanding of the literature (Appendix 2 and 3). For each data set, we report the meta-analytical 
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summary effect estimates and 95% confidence intervals for fixed and random effects models, as well as 
heterogeneity statistics. For the COPD data, heterogeneity was small in all analyses. However, 
considering MID to have a distribution of values (with rho=0.5 and CoVMID set to 0.8) instead of being a 
constant considerably 1) decreased the point estimate towards the null and 2) increased the 95% 
confidence intervals in both fixed and random effects models. In data from patients with osteoarthritis, the 
heterogeneity of the data was considered much greater when MID was considered a constant. Considering 
MID as a distribution instead of a constant also shifted the point estimates towards the null in both fixed 
and random effects models. Although the absolute width of the 95% confidence intervals in fixed effects 
models was considerably increased, it slightly decreased in random effects models.  
Table 2 presents similar results to Table 1, and shows the changes in effect estimates and 95% 
confidence intervals when CoVMID is held constant at 0.5, and rho is varied between 0.0, 0.5 and 0.8. The 
results and interpretations are similar to Table 1.  
Presentation for Decision-Makers 
In a recent GRADE article [26], the authors outlined different presentation options for continuous 
outcomes in summary of findings tables, including the use of MDMID units. However, the choice for 
MDMID presented listed only the comparative option (as the difference in MDMID.) In fact, all presentation 
formats for SMD can be applied to MDMID units, with similar but more transparent assumptions. In both 
cases, the outcome is a continuous scale with no limits on either end of the scale, and the approach is 
almost identical. We reproduced the results of Table 5 in Guyatt et al [26] as shown in Table 3, and added 
how one would provide similar results in MDMID units (assumptions and calculations provided in 
Appendix 4), as well as some additional options we believe may be more meaningful to some patients. 
With identical presentation options, and the reduced risk of bias in estimating the treatment effect with 
MDMID when MID is a random variable with a distribution, we believe the MDMID approach should 
become the preferred method compared to the SMD approach when different continuous measures are 
used across studies to evaluate the same construct. 
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DISCUSSION 
We have reviewed the meta-analytical implications that occur when the MID represents a 
distribution of values rather than a single value. Our approach avoids the assumptions that 1) MID should 
be considered constant across a single scale and for different patients, 2) the CoVMID is independent of the 
measure and 3) there is no correlation between the MID and the MD of different scales. In sensitivity 
analyses using the original data describing MDMID and setting the true rho at 0.5 and the true CoVMID at 
0.8, assuming MDMID to be a constant would overestimate the treatment effect by 33% for COPD quality 
of life, and decrease the p-value for heterogeneity from 0.99 to 0.08. Similar or greater magnitudes of 
results were obtained in sensitivity analyses if rho=0.8 and CoVMID =0.5 in this data set, and for studies 
examining pain and disability in patients with osteoarthritis. However, we highlight that CoVMID were not 
available for the particular measures and we used the same value for each measure. Different results 
would be obtained if the CoVMID were known and allowed to differ across measures, and there are 
minimal effects if rho and CoVMID are small. This highlights the need for authors to comment on how 
realistic their assumptions are when imputing values for these variables, such as assuming MID is 
constant. 
Meta-analyses of continuous outcomes represent a challenge because different investigators often 
use different scales to measure the same construct. For example, the meta-analysis for patients with 
osteoarthritis included 18 different scales for pain, and 12 different scales for disability. Although the 
SMD allows investigators to combine the results mathematically, there are important limitations as we 
described earlier. Perhaps more importantly, the ultimate objective of a meta-analysis is to help patients, 
clinicians and policy makers take decisions. The clinical interpretation of the SMD is difficult. What does 
a difference of 0.3 standard deviations really mean for a patient trying to evaluate if a treatment benefit is 
worth the associated side effects? Explaining that this is a small or moderate effect is not that helpful, 
even if one ignores the limitations of the arbitrary effect size cut-offs that are often applied [31]. The 
RoM approach proposed by Friedrich et al. [21, 22] is helpful if one believes the treatment acts on a 
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multiplicative scale. Explaining that pain is reduced by 50% is easily understandable, and is appropriate 
as long as the reduction is indeed 50% regardless of the baseline pain within the ranges studied. The 
MDMID provides for a similar ease of interpretation and also incorporates a clinically meaningful 
perspective on magnitude of effect. Like the SMD, this is on the additive scale (treatment reduces pain by 
2 points regardless of baseline value in the range of the studies) but without the challenges of the SMD.  
In the original description on how to obtain an MID, the investigators questioned many 
participants and then used the mean value [32]. One way to think about the magnitude of potential bias is 
to think about signal-to-noise ratios. If MID is considered a constant, obtaining a precise estimate of the 
true MID is essential because even a small difference is recognized as bias. However, if there is some 
noise (i.e. variability/variance) in the signal, then small changes in the point estimate are somewhat 
masked by the noise/variance. Another perspective is that the variance in the MID measure is a 
combination of systematic error (bias), sampling error and inter-participant heterogeneity. With proper 
sampling techniques, there should not be systematic bias. The traditional method for estimating MID 
requires many participants to minimize sampling error. However, in reality, the total variance will usually 
be dominated by the inter-participant heterogeneity, and therefore increasing sampling size above a 
certain threshold (which would depend on context) will not have much of an effect. Therefore, optimal 
sample sizes of participants for eliciting MID will usually be considerably smaller, leading to easier 
methods and MID calculations for more instruments. More recently, Copay et al. reviewed several 
different methods to obtain an MID and all of them include simplifying a distribution into a single value. 
We believe acknowledging and incorporating the true variation in the MID is important because the 
variation partly reflects personal values and context, and partly reflects that MID could vary according to 
baseline values [28, 29], whether expressed on absolute or relative scale. Ignoring this variation and 
considering the MID as a constant equal to the mean of this distribution introduces significant challenges 
for calculating the variance of MDMID in meta-analyses. First, it inappropriately suggests a precision that 
is not correct. Second, it requires omitting studies that do not have an MID already calculated, or using a 
method that assumes the MID/sd ratio is constant across all scales measuring the same construct [24]. 
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Considering the MID as a random variable allows investigators to make more realistic assumptions about 
the distribution based on their substantive knowledge and clinical experience, and apply appropriate 
sensitivity analyses based on the mean, CoVMID and rho.  
We used the delta method to approximate the variance for the MDMID. The delta method is 
commonly used to obtain an approximate variance for non-linear functions of random variables such as 
ratios [34, 35]. The focus of this paper was not a statistical assessment of optimality properties of 
estimators for parameters of interest, as one would typically do in methods performance assessment in the 
context of estimation as well as hypothesis testing. A comprehensive simulation study to assess optimality 
properties for estimators (e.g., bias and mean square error) and corresponding test statistics (e.g., Type I 
error and statistical power) was beyond the scope of this paper. However, there are some known 
limitations when ratios are the functions of interest, as in our application. First, complications can arise 
when the denominator gets close to zero. Second, statistical inference (e.g., confidence intervals) assumes 
that the bivariate random vector consisting of the numerator and denominator is distributed as bivariate 
normal (exactly or approximately). This assumption is likely to be violated when sample size is small or 
when there are outliers. Third, the effect we observed due to CoVMID and rho is greatest for those studies 
with the largest mean difference. Studies using measures that are sensitive to change would be expected 
to have higher mean differences, which might lead to a greater variance and inappropriately down 
weighting. For example, increasing CoVMID had the greatest effect on the variance of the Behnke 2000 
study (study “f”), which means this study (with a large effect) might receive a lower weight when MID is 
considered random variable. However, these studies with greater sensitivity to change are also expected to 
have a smaller CoVMID because there is less “noise” or error in the measure of improvement, which leads 
to a reduced variance and up weighting. Which of these two effects would predominate, and the overall 
effect on the relative weighting of studies in any particular meta-analysis, is difficult to predict.  Fourth, 
regardless of how one estimates the effect in MID units (e.g. anchor based methods, distribution based 
methods), one must always estimate a value for rho and CoVMID, which may be from observed data, 
substantive knowledge or guessing. Although we applied the same CoVMID and rho to each measure in 
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our sensitivity analyses to illustrate why it is important to consider the MID as a random variable with a 
distribution, we emphasize that best practice would be to estimate a separate CoVMID and rho for each 
measure, through either observed data or substantive knowledge. If observed data or substantive 
knowledge are not available, then investigators should decide if it is reasonable to assume a value of 0 for 
both variables. The methods described in this paper can be used to estimate how the results may be under 
or overestimated, should the true values be different from 0. Finally, if sensitivity to change is quite 
different for different measures, investigators should carefully consider whether it is appropriate to 
combine these studies in a meta-analysis, whether MID is considered a constant or as having a 
distribution.  
CONCLUSIONS 
The objective of a meta-analysis is to help make informed decisions. The MDMID is an easily 
interpretable measure of effect for patients, clinicians and decision makers. Considering the MID as a 
random variable with a mean and sd instead of a constant allows for a more appropriate estimate of the 
variance, and thus a more appropriate estimate of treatment effects. 
 
ABBREVIATIONS 
EBM: Evidence-based medicine 
WOMAC: Western Ontario and McMaster University Osteoarthritis Index 
KOOS: Knee Injury and Osteoarthritis Outcome Score 
HOOS: Hip Disability and Osteoarthritis Outcome Score 
HAQ: Health Assessment Questionnaire 
AIMS: Arthritis Impact Measurement Scales 
MD: Mean Difference (Mean Group 1 – Mean Group 2) 
sd: standard deviation 
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SMD: Standardized Mean Difference (MD/sd) is the mean difference expressed in sd units 
RoM: Ratio of Means (Mean Group 1 / Mean Group 2) 
MID: Minimal Important Difference 
MDMID: Mean Difference expressed in MID units 
CoVMID: coefficient of variation of the MID 
sdMID: standard deviation of the MID distribution 
meanMID: mean of the MID distribution 
sdMeanDiff: pooled sd of the two groups being compared 
MeanDiff: mean difference 
COPD: Chronic obstructive pulmonary disease 
CRQ: Chronic respiratory disease questionnaire 
SGRC: St. Georges Respiratory questionnaire 
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Figure Legends 
Figure 1. Meta-analysis of health related quality of life for rehabilitation of chronic obstructive pulmonary 
disease based on data presented in Johnston et al. [23] with the effect estimate presented as a mean 
difference between groups using a scale of MID units. The questionnaires were the St. Georges 
Respiratory Questionnaire (SGRC: MID reported as 4 points on a 100-point scale) and Chronic 
Respiratory Disease Questionnaire (CRQ: MID reported as 0.5 on a 7-point scale). Our figure is 
minimally different from Figure 2 in Johnston et al because we used the raw numbers in their Figure 1 to 
generate the meta-analysis (there were small discrepancies between “n” in Figures 1 and 2), and also 
corrected some minimal mathematical errors. 
 
Figure 2: The square root of the variance (sd, to provide more spread between the points) when MID 
(minimal important difference) is a constant is plotted against the square root of the variance (delta 
method) when MID is considered a random variable, when the correlation between the mean difference 
between groups and the MID is held constant at 0.5, and the coefficient of variation for MID (sd of MID / 
mean MID) is varied between 0.2, 0.5 and 0.8. The studies are labeled with letters corresponding to the 
numbers with each study in Figure 1. Points that are below the line of identity indicate that considering 
MID as a constant will underestimate (and points above the line of identity will overestimate) the variance 
given the values of rho and coefficient of variation for MID of the specified simulation. 
 
Figure 3. The square root of the variance (sd, to provide more spread between the points) when MID 
(minimal important difference) is a constant is plotted against the square root of the variance (delta 
method) when MID is considered a random variable, when the correlation between the mean difference 
between groups and the MID (rho) is varied between 0, 0.5 and 0.8, and the coefficient of variation for 
MID (sd of MID / mean MID) is held constant at 0.5.The studies are labeled with letters corresponding to 
the numbers with each study in Figure 1. Points that are below the line of identity indicate that 
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considering MID as a constant will underestimate (and points above the line of identity will overestimate) 
the variance given the values of rho and coefficient of variation for MID of the specified simulation.  
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Table 1. The effect of varying the coefficient of variation of minimal important difference (CoVMID) on meta-analysis results# when the 
correlation (rho) between the minimal important difference (MID) and mean difference is equal to 0.5. Outcome measures 
include changes in quality of life with treatment for chronic obstructive pulmonary disease (COPD-QOL) (data from Johnson et 
al [23]), changes in Pain (OA-Pain) and Disability (OA-Disability) with exercise for osteoarthritis (data from [25]).  
     Heterogeneity Statistics 
Outcome Rho CoVMID Fixed effect Random effect I-squared Tau-squared p-value 
COPD-QOL MID as a Constant 1.79 (1.51 to 2.07) 1.74 (1.35 to 2.12) 35% 0.1895 0.08 
 0.5 0.2 1.67 (1.40 to 1.94) 1.69 (1.34 to 2.03) 29% 0.1319 0.13 
 0.5 0.5 1.47 (1.07 to 1.87) 1.47 (1.07 to 1.87) 0% 0 0.95 
 0.5 0.8 1.35 (0.77 to 1.92) 1.35 (0.77 to 1.92) 0% 0 0.99 
       
OA-Pain MID as a Constant -0.13 (-0.16 to -0.11) -0.29 (-0.36 to -0.21) 77% 0.0245 <0.0001 
 0.5 0.2 -0.11 (-0.15 to -0.08) -0.21 (-0.28 to -0.14) 48.8% 0.0125 0.0012 
 0.5 0.5 -0.09 (-0.14 to -0.04) -0.09 (-0.14 to -0.04) 0% 0 0.56 
 0.5 0.8 -0.08 (-0.15 to -0.02) -0.08 (-0.15 to -0.02) 0% 0 0.98 
       
OA-Disability MID as a Constant -0.21 (-0.25 to -0.17) -0.28 (-0.37 to -0.18) 78.3% 0.0428 <0.0001 
 0.5 0.2 -0.16 (-0.21 to -0.11) -0.19 (-0.27 to -0.12) 36.4% 0.0115 0.024 
 0.5 0.5 -0.12 (-0.19 to -0.06) -0.12 (-0.19 to -0.06) 0% 0 0.84 
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 0.5 0.8 -0.10 (-0.17 to -0.02) -0.10 (-0.17 to -0.02) 0% 0 0.99 
#
 Results are expressed as mean differences in MID units with 95% confidence intervals for both fixed effects and random effects 
models, along with I-squared, tau-squared and the p-value for heterogeneity. When MID is considered a constant, rho and CoV equal 0, 
and therefore only one value is provided for each outcome. When rho was set to 0.8 (results not shown), the results were similar with 
only minimal decreases in the effect estimates and measures of heterogeneity, although the 95% confidence interval for rho=0.8 and 
ratio=0.8 reached or crossed 0 for osteoarthritis outcomes [fixed and random effect estimates -0.05 (-0.11 to 0.01) for pain; fixed and 
random effect estimates -0.08 (-0.15 to 0.00) for disability]. 
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Table 2. The effect of varying the correlation (rho) between the minimal important difference (MID) and mean difference on meta-
analysis results#, when coefficient of variation of minimal important difference (CoVMID) is equal to 0.5. Outcome measures 
include changes in quality of life with treatment for chronic obstructive pulmonary disease (COPD-QOL) (data from Johnson et 
al publication), changes in Pain (OA-Pain) and Disability (OA-Disability) with exercise for osteoarthritis. 
     Heterogeneity Statistics 
Outcome Rho CoVMID Fixed effect Random effect I-squared Tau-squared p-value 
COPD-QOL MID as a constant 1.79 (1.51 to 2.07) 1.74 (1.35 to 2.12) 35% 0.1895 0.08 
 0.2 0.5 1.61 (1.26 to 1.97) 1.61 (1.26 to 1.97) 0% 0 0.62 
 0.5 0.5 1.43 (0.90 to 1.96) 1.43 (0.90 to 1.96) 0% 0 0.98 
 0.8 0.5 1.28 (0.57 to 2.00) 1.28 (0.57 to 2.00) 0% 0 0.99 
        
OA-Pain MID as a constant -0.13 (-0.16 to -0.11) -0.29 (-0.36 to -0.21) 77% 0.0245 <0.0001 
 0.2 0.5 -0.12 (-0.15 to -0.09) -0.24 (-0.31 to -0.17) 61.6% 0.0158 <0.0001 
 0.5 0.5 -0.10 (-0.15 to -0.06) -0.15 (-0.21 to -0.09) 14.2% 0.0032 0.24 
 0.8 0.5 -0.10 (-0.15 to -0.04) -0.10 (-0.15 to -0.04) 0% 0 0.95 
        
OA-Disability MID as a constant -0.21 (-0.25 to -0.17) -0.28 (-0.37 to -0.18) 78.3% 0.0428 <0.0001 
 0.2 0.5 -0.17 (-0.21 to -0.13) -0.22 (-0.30 to -0.15) 51.8% 0.0165 0.0005 
 0.5 0.5 -0.14 (-0.20 to -0.09) -0.14 (-0.20 to -0.09) 0% 0 0.6048 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
 28
 0.8 0.5 -0.12 (-0.19 to -0.05) -0.12 (-0.19 to -0.05) 0% 0 0.98 
#
 Results are expressed as mean differences in MID units with 95% confidence intervals for both fixed effects and random effects 
models, along with I-squared, tau-squared and the p-value for heterogeneity. When MID is considered a constant, rho and CoV equal 0, 
and therefore only one value is provided for each outcome. 
 
  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
 29
Table 3: Different recommended formats for the GRADE Summary of Findings tables [26] using health related quality of life data from 
Johnston as the example. Italicized rows are new suggestions not represented in [26] based on the premise that decision-makers should be 
given two numbers to compare, rather than one number and a comparative estimate that has to be converted to a second number [36].  
Outcome 
Estimated baseline score/ 
proportion improving in 
control patients 
Estimated baseline score/ proportion 
improving in treatment patients 
Certainty of 
the Evidence Comments 
Comparative Estimate 
Quality of Life 
(sd units) 
The HRQL score in the respiratory rehabilitation group improved on 
average 0.73 (95%CI: 0.49 to 0.96) more sd units in the respiratory 
rehabilitation patients than in the control patients  
♁?♁?♁?♁?  
High
As a rule of thumb, 0.2 sd represents a 
small difference, 0.5 a moderate, and 0.8 a 
large  
Quality of Life 
(MID units) 
The HRQL score in the respiratory rehabilitation group improved on 
average an extra 1.47 (1.07 to 1.87) MID units compared to control 
patients  
♁?♁?♁?♁?  
High 
Estimated assuming a moderate (0.5) 
correlation between variation in MID and 
the mean difference on a scale, and 
moderate variability in what is considered 
the MID itself. 
Mean of each Group 
Quality of Life 
(from sd units 
and HRQOL 
scale 1-7)a 
Control group baseline, 4.5a  
Average improvement in 
control was 0.04 
HRQL improved on average 0.73 
(95%CI: 0.49 to 0.96) sd units more 
in the respiratory rehabilitation 
patients than in the control patients  
♁?♁?♁?♁?  
High 
Calculated by transforming all scores to the 
CRQ in which the minimally important 
difference is 0.5, and multiplying 0.01 sd 
unit mean by 7 
Quality of Life 
(MID units)a 
Average improvement in 
control was 0.08 MID units 
HRQL improved on average 1.47 
(95%CI: 1.07 to 1.87) MID units 
more in the respiratory rehabilitation 
patients than in the control patients  
♁?♁?♁?♁?  
High 
Average in control group calculated as the 
median of all control group scores 
expressed in MID units  
Quality of Life 
(MID units)a 
Average improvement in 
control was 0.08 MID units 
Average improvement in treated 
group was 1.55 (95%CI: 1.15 to 
1.95) MID units b 
♁?♁?♁?♁?  
High 
Average in control group calculated as the 
median of all control group scores 
expressed in MID units 
Proportion of Patients in each Group with Important Improvement c 
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Based on sd 
units 0.3
d
 
Differences in proportion achieving 
important improvement 0.31 (95% 
CI: 0.22, 0.40) in favor of 
rehabilitation 
♁?♁?♁?♁?  
High 
Calculation uses established minimally 
important difference of 0.5 units on the 
CRQ and 4 units on the St. George’s 
Respiratory Questionnaire  
Based on MID 
units 
0.18 achieved important 
improvement 
Differences in proportion achieving 
important improvement 0.53 
(95%CI: 0.48 to 0.65) in favor of 
rehabilitation e 
♁?♁?♁?♁?  
High 
Calculation uses 1 MID as the definition for 
Important Improvement and assumes a 
normal distribution for subjects’ scores. 
Quality of Life 
(MID units) 
0.18 achieved important 
improvement 
0.71 (95%CI: 0.56 to 0.83) achieved 
important improvement b 
♁?♁?♁?♁?  
High
Calculation uses 1 MID as the definition for 
Important Improvement and assumes a 
normal distribution for subjects’ scores. 
a
 Approximate average of baseline control group scores in the studies that reported the baseline score (numbers from [26]). 
b Calculated by summing the control group improvement and the treatment effect 
c
 The assumptions underlying these calculations were not provided in [26]. See Appendix 4 for details. 
d
 This represents the median of the proportion of patients in the control group who achieved an important improvement. That is, the 
proportion with improvement was calculated for each study [more than 0.5 (CRQ) or 4 (St. George’s)], and the median of these values 
was 0.3, suggesting 30% of the control group achieved an important improvement. 
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Appendix 1: Using the delta method, the variance of the ratio is traditionally written as [30] 
 
  3

4 =
 !"#
$!"%# − '2 ∗ rho ∗ sd/0 ∗ sd/=0 ∗ 3
/0
$!"%#>45	+	
/0∗?@"%#
$!"%#A  [eq.A1] 
 
where MD is the mean difference between groups, MID is the proposed minimal important difference for 
the scale being used, varianceMD is the variance of the difference in the group means, meanMID is the mean 
of the MID distribution (equal to the value of MID when MID is considered a constant), rho is the 
correlation between varianceMD and meanMID, and sdMD is the pooled sd (between the two groups). 
Rearranging the formula, highlights the effect of CoVMID: 
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Appendix 2: Values of minimal important difference (MID) for studies on examining the effect of 
exercise on pain in patients with osteoarthritis. 
Author Year Scale MID 
Minor 1989 AIMS (sum of 4 items standardized; range 0-10) 2 
Kovar 1992 AIMS (1 ordinal scale standardized; range 0-10) 3 
Ettinger (a) 1997 CPS (mean of 6 items; range 1-6) 1.5 
Ettinger (b) 1997 CPS (mean of 6 items; range 1-6) 1.5 
Bautch 1997 VAS (mean of 2 VAS; range 0-10) 2 
Rogind 1998 NRS (one 11 box pain scale; range 0-10)  3 
van Baar 1998 VAS (1 VAS; range 0-100) 20 
Peloquin 1999 AIMS 2 (mean of 5 items standardized; range 0-10) 2 
Maurer 1999 WOMAC (sum of 5 VAS; range 0-500) 100 
O'Reilly 1999 WOMAC (sum of 5 items scored 0 to 4; range 0-20) 6 
Hopman-Rock 2000 VAS (1 VAS; range 0-100) 20 
Deyle 2000 WOMAC (sum of 5 VAS; range 0-500) 100 
Petrella 2000 WOMAC (sum of 5 items scored 0 to 4; range 0-20) 6 
Baker 2001 WOMAC (sum of 5 VAS; range 0-500) 100 
Fransen 2001 WOMAC (mean of 5 items scored 0 to 4; range 0-
100) 
20 
Gur 2002 NRS11 (sum of 7 11-box NRS scored 0-10; range 0-
70) 
21 
Thomas 2002 WOMAC (sum of 5 items scored 0 to 4; range 0-20) 6 
Topp 2002 WOMAC (sum of 5 items scored 0 to 4; range 0-20) 6 
Talbot 2003 McGill Pain Questionnaire (1 ordinal scale; range  0-
5) 
1 
Huang 2003 VAS (Walk-Stand) (1 VAS; range 0-10) 2 
Quilty 2003 VAS (Pain Overall) (1 item scored 0-100) 20 
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Foley 2003 WOMAC (sum of 5 items scored 0 to 4; range 0-20) 6 
Song 2003 WOMAC (sum of 5 items scored 0 to 4; range 0-20) 6 
Keefe 2004 AIMS (mean of 4 items standardized; range 0-10) 2 
Hughes 2004 WOMAC (sum of 5 items scored 0 to 4; range 0-20) 6 
Messier 2004 WOMAC (sum of 5 items scored 0 to 4; range 0-20) 6 
Thorstensson 2005 KOOS (9 items scored 0-4, standardized; range 0-
100) 
10 
Huang a 2005 VAS (Walk-Stand) (1 item scored 0-10) 2 
Bennell 2005 VAS (Pain Move) (1 item scored 0-10) 2 
Hay 2006 WOMAC  (sum of 5 items scored 0 to 4; range 0-20) 6 
Mikesky 2006 WOMAC (sum of 5 items scored 0 to 4; range 0-20) 6 
Fransen 2007 WOMAC (mean of 5 items scored 0 to 4; range 0-
100) 
30 
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Appendix 3: Values of minimal important difference (MID) for studies on examining the effect of 
exercise on disability in patients with osteoarthritis. 
Author Year Scale MID 
Minor 1989 AIMS (physical activity) (sum of 5 items standardized; range 0-10) 2 
Kovar 1992 AIMS (physical activity) (sum of 5 items standardized; range 0-10) 2 
Schilke 1996 OASI (mobility) (mean of VAS; range 0-10) 1.7 
Bautch 1997 AIMS (disability) (sum of 45 items scored 0-1; range 0-45) 13.5 
Ettinger a 1997 23 questions on disability (mean of 23 items; range 1-5) 1.5 
Ettinger b 1997 23 questions on disability (mean of 23 items; range 1-5) 1.5 
Rogind 1998 Algofunctional Index (AFI) (sum of 10 items; range 0-24) 3.5 
van Baar 1998 Impact of rheumatic diseases on health and lifestyle (sum of 7 items scored 1-4; range 7-28) 4.4 
Maurer 1999 WOMAC Disability (sum of 17 items scored 0-100; range 0-1700) 340 
O'Reilly 1999 WOMAC Disability (sum of 7 items scored 1-4; range 7-28) 13.6 
Peloquin 1999 AIMS 2(walking and bending) (mean of 5 items standardized; 
range 0-10) 2 
Deyle 2000 WOMAC Disability (sum of 17 items scored ; range 0-1700) 340 
Hopman-Rock 2000 Impact of rheumatic diseases on health and lifestyle (mobility) (sum of 7 items scored 1-4; range 7-28) 4.4 
Petrella 2000 WOMAC Disability (100 mm scale) (mean of 17 VAS; range 0-10) 2 
Baker 2001 WOMAC Disability (sum of 17 VAS; range 0-1700) 340 
Fransen 2001 WOMAC Disability (mean of 17 VAS; range 0-100) 20 
Gur 2002 NRS (sum of 7 items scored 0-10; range 0-70) 15 
Thomas 2002 WOMAC Disability (sum of 17 items scored 0-4; range 0-68) 13.6 
Topp 2002 WOMAC Disability  (sum of 17 items scored 0-4; range 0-68) 13.6 
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Foley 2003 WOMAC Disability  (sum of 17 items scored 0-4; range 0-68) 13.6 
Huang 2003 Lequesne (sum of 11 items; range 0-26) 5.2 
Quilty 2003 WOMAC Disability  (sum of 17 items scored 0-4; range 0-68) 13.6 
Song 2003 WOMAC Disability  (sum of 17 items scored 0-4; range 0-68) 13.6 
Hughes 2004 WOMAC Disability  (sum of 17 items scored 0-4; range 0-68) 13.6 
Messier 2004 WOMAC Disability  (sum of 17 items scored 0-4; range 0-68) 13.6 
Bennell 2005 WOMAC Disability  (sum of 17 items scored 0-4; range 0-68) 13.6 
Huang a 2005 Lequesne (sum of 11 items; range 0-26) 5.2 
Thorstensson 2005 KOOS (ADL) (sum of 17 items standardized; range 0-100) 20 
Hay 2006 WOMAC Disability  (sum of 17 items scored 0-4; range 0-68) 13.6 
Mikesky 2006 WOMAC Disability  (sum of 17 items scored 0-4; range 0-68) 13.6 
Fransen 2007 WOMAC Disability  (mean of 17 items scored; range 0-100)) 20 
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Appendix 4: Explanation of assumptions for presentation of proportions in the GRADE Summary of 
Findings table. 
 
One method to calculate the proportion improved for a control group in a single study is: 
Φ8:C −DEFGFH;IJEFGFH < 
where Φ is the cumulative standard normal distribution, C is the cutoff threshold, and meanControl and 
sdControl are the mean and sd of the control group respectively [37, 38]. In brief, this equation is based on a 
standard normal distribution with mean equal to 0 and sd equal to 1. The cutoff threshold is then shifted 
to what it would have been for this distribution by subtracting the mean of the observed data from the 
threshold. One then calculates the probability of being above the adjusted threshold. This is equivalent to 
creating a cumulative normal distribution with mean and sd equal to the observed data, and calculating 
the probability of being above the threshold.  
 
We now have to expand this concept to accommodate meta-analysis. The first step is to estimate the 
overall control mean and sd for all the studies combined. From the footnote in Table 5 in the GRADE 
paper [26], it appears the authors calculated the probability of improvement for each study, and then took 
the median of these probabilities. However, this approach gives equal weight to each study and ignores 
the normal meta-analytical approach of weighting studies. Alternatively, one could take a weighted mean 
or weighted median of the results in the controls and use these values for the calculation of probability of 
improvement. Because our purpose is simply to demonstrate the presentation of results and rather than 
reporting valid estimates, we used the apparent methods in [26] in order to avoid confusion. 
 
We now turn our attention to the proportion improved in the treatment group. Simply applying the same 
methods to the treatment group as one did for the control group would effectively be ignoring 
randomization and treating the control and treatment groups as completely separate studies. The methods 
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in [26] are not provided for calculating proportion improved when using MID units. We were able to 
approximate their results (0.32 increased improvement versus 0.31 increased improvement) by 
considering the treatment mean to be the difference in means (0.71) plus the control mean (0.04). 
However, this method does not require the comment in the table detailing the MID for CRQ and SGRC 
questionnaires. 
 
For the calculations in our table using only MID units, we first calculated the mean change in MID units 
for the control group using the same unweighted methods in [26] in order to be consistent (0.08 MDMID 
units). We then calculated the proportion improved in the control group considering MID equal to 1 as the 
important difference and an sd equal to 1. The mean of the treatment group is calculated by adding the 
treatment effect in MDMID units with rho = 0.5 and CoV = 0.5 [1.47 (1.07 to 1.87)] to the mean of the 
control group (0.08), which yields was 1.55 (95%CI: 1.15 to 1.95). We then calculated the overall 
proportion improved in the treatment group using these mean values, and the overall difference in 
proportions improved was simply the difference between the proportion improved in the treatment group 
and the proportion improved in the control group. 
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